Why the study?
Transcatheter MVIV and MVIR replacement are feasible alternatives to reoperation for bioprosthetic mitral structural valve degeneration and failed mitral valve repair, but comparative data are lacking.
Does transcatheter mitral valve-in-valve or valve-in-ring replacement improve outcomes compared to reoperative mitral surgery in patients with structural valve degeneration or failed mitral valve repair?
Does transcatheter mitral valve-in-valve or valve-in-ring replacement improve outcomes compared to reoperative mitral surgery in patients with structural valve degeneration or failed mitral valve repair?
MVIV is a viable alternative to redo-MVR for structural valve degeneration with similar 1-year mortality, whereas reoperative surgery remains preferred for failed mitral valve repair due to suboptimal results with MVIR.
No takes yet. Share an insight, caveat, or question.
Supports MVIV as alternative to redo-MVR for structural valve degeneration; extends comparative evidence for transcatheter mitral options.
Sengupta et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: